Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. It also develops, manufactures, and distributes various health care products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, physician nephrology, ambulant treatment, and other services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics, as well as through local sales forces, independent distributors, dealers, and sales agents. Fresenius Medical Care AG was incorporated in 1996 and is headquartered in Bad Homburg, Germany.

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an)

Fresenius Medical Care AG & Co. KGaA received a Sell rating and a €37.00 price target from UBS analyst Graham Doyle today. According to TipRanks, D...

UBS downgrades Fresenius Medical Care AG & Co. KGaA (0H9X) to a Sell

In a report released on May 5, Oliver Reinberg from Kepler Capital maintained a Hold rating on Fresenius Medical Care AG & Co. KGaA, with a price t...

Kepler Capital  Sticks to Its Hold Rating for Fresenius Medical Care AG & Co. KGaA (0H9X)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Neurocrine (NBIX), Fresenius Medical Care (FMS) an...

Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Fresenius Medical Care (FMS) and American Well (AMWL)

Fresenius Medical Care ( ($FMS) ) has shared an announcement. Fresenius Medical Care filed a Form 6-K in May 2026 providing an interim report on it...

Current Quarter	$NA	Next Quarter	$NA
Current Year	$2.24	Next Year	$2.43
QoQ Growth	NaN%	YoY Growth	+8.5%
3Y EPS CAGR	+0.0%	Target Price	$24.30
Consensus	Buy	Upside	+12.6%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	FMS	$21.58	-0.28%	677.46K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	FMS	$21.58	-0.3%	677.46K
3
4
5
6

FMS

FMS

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an) Data in Excel

Get Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an) Data in Excel